Linlong Xue

Consultant on Assays for PROTAC/Glue and covalent small molecules @ Independent Consultant

About

Experienced biochemist with 17+ years in drug discovery biochemistry and biophysics, with a track record of leading cross-functional teams from early target validation through clinical candidate selection. Established Biogen’s first internal ASMS screening capability and led biophysics programs spanning neurodegeneration (AD, PD, HD), oncology, and ophthalmology. Deep expertise in SPR, TR-FRET, HTS, PROTACs, covalent inhibitors, and molecular glue platforms. First-author publications in Cell and Biochemistry; research highlighted by Nature and C&EN.

Country

United States

City

Suffolk County

Industry

Pharmaceuticals

Skill

Drug Discovery, High Throughput Screening, Protein expression and purification, FPLC, HPLC, Drug metabolism, biochemical assay, biophysical assay, cell-based assay, Protein Chemistry, Assay Development, Purification, Protein Expression, Molecular Cloning, Biochemistry, Cell Biology, Cell, Cell Culture, Medicinal Chemistry, Protein Purification

Experience

Consultant on Assays for PROTAC/Glue and covalent small molecules

Independent Consultant

2025-3 - Present · 1 yr 7 mos

Boston, MA

• Provide bioassay consulting on covalent inhibitor and molecular glue/PROTAC small-molecule projects for an academic laboratory. • Contributing part-time to a stealth-stage biotech startup: strategy analysis, target selection, and business planning.

Senior Scientist to Associate Scientific Director

Biogen

2018-7 - 2025-2 · 6 yrs 8 mos

Cambridge, MA

• Led a biophysics group of 3–4 scientists providing assay support to 3–5 concurrent small-molecule programs annually across AD, PD, HD, and MS therapeutic areas. • Drove early-stage small-molecule target discussions within BTMS, including target selection, project prioritization, and cross-functional resource alignment. • Led internal biophysical assays (SPR, MST, NMR) for 3 RNA splicing modulator projects, enabling go/no-go decisions on challenging targets. • Spearheaded Biogen’s first ASMS screen of a 50K-compound library against a membrane protein and a protein complex at CROs, identifying new chemical matter and directly enabling the build-out of an internal ASMS platform subsequently applied to multiple programs. • Led DEL screen at a CRO against a GPCR target, identifying novel scaffolds with drug-like properties. • Founded and led Biacore/BLI/Caterra user community within Biogen, fostering knowledge-sharing on SM-protein and mAb-antigen interaction technologies. • Managed end-to-end CRO collaborations (PROTAC, ASMS, DEL, SPR): vendor selection, SOW negotiation, data QC, and weekly technical reviews.

Senior Scientist

Warp Drive Bio, LLC

2014-11 - 2018-7 · 3 yrs 9 mos

Cambridge, MA

• Built HTS platform, screening >30K compounds to identify validated molecular glue hits for K-Ras and additional oncology targets. • Led assay development and HTS campaigns using SPR/Octet, FP, TR-FRET, AlphaScreen, and enzymatic assays focused on protein-protein interactions. • Developed MS-based assay for measuring Kinact/Ki of covalent inhibitors. • Managed CRO partnerships for protein production and biophysical assays (SPR, NMR); oversaw internal protein expression and purification.

Research Scientist II

The Broad Institute of MIT and Harvard

2010-10 - 2014-5 · 3 yrs 8 mos

• Developed and executed HTS assays for challenging, undruggable targets using AlphaScreen, AlphaLISA, DEPHIA, DSF, FP, SPR, and ITC. • Developed methods for expression and purification of transcription factors in insect cells; conducted cell-based compound potency assays. • Managed institute-wide AKTA FPLC instrumentation and trained users.

Consultant Scientist

Merck

2009-3 - 2010-10 · 1 yr 8 mos

1. Protein Production from E. Coli, Insect cells and CHO 2. Downstream characterization of the produced proteins. 3. FRET-based assay developement and hit compound screening